2011 J.P. Morgan Healthcare Conference Features China Track
For the first time in its 29 years, the J.P. Morgan Healthcare Conference will include a track focused specifically on China. On Wednesday, January 12, fourteen China-based life science companies will present their plans to interested investors. The special track gives implicit recognition by this important US conference that China has become a critical part of international ***a.
The J.P. Morgan Healthcare Conference provides a forum for life science companies, most of which are publicly held, to make their business cases to investors. It is a “must attend” event for most life science executives, and that now includes leaders of China-based companies. The Conference will be held January 10-13 in San Francisco at the Westin St. Francis Hotel.
In addition to the presenting companies, the China track also includes a panel that will discuss the theme “The China Healthcare Market Operating Environment.”
The following is the preliminary list of companies presenting in the China track:
? Golden Meditech Holdings, Ltd. (HKEX: 801)
? Simcere Pharmaceutical Group (NYSE: SCR)
? Hutchison MediPharma Ltd. (AIM: HCM)
? Concord Medical Services Holdings Ltd. (NYSE: CCM)
? Sinopharm Holding Co. Ltd. (HKEX: 1099)
? Bicon Pharmaceutical Holdings Ltd. (privately held)
? China Resources Medications Group Ltd. (privately held)
? 3SBio Inc. (NSDQ: SSRX)
? ShangPharma Corp. (NYSE: SHP)
? Eddingpharm Inc. (privately held)
? China Kanghui Holdings (NYSE: KH)
? Shanghai Fosun Pharmaceutical (Group) (SHEX: 600196)
? Chindex International, Inc. (NYSE: CHDX)
? Novast Holdings, Ltd. (privately held).
Representatives of ChinaBio? will be attending the Conference and are available to discuss China’s life science sector. (Please email jpm2011@chinabiollc.com.) Greg Scott, ChinaBio’s CEO and founder, will also be speaking on Thursday, January 13, at the New Paradigms conference on funding opportunities in China and elsewhere in Asia (http://www.theconferenceforum.org/NewParadigms-Overview.html).
Disclosure: none.
For the first time in its 29 years, the J.P. Morgan Healthcare Conference will include a track focused specifically on China. On Wednesday, January 12, fourteen China-based life science companies will present their plans to interested investors. The special track gives implicit recognition by this important US conference that China has become a critical part of international ***a.
The J.P. Morgan Healthcare Conference provides a forum for life science companies, most of which are publicly held, to make their business cases to investors. It is a “must attend” event for most life science executives, and that now includes leaders of China-based companies. The Conference will be held January 10-13 in San Francisco at the Westin St. Francis Hotel.
In addition to the presenting companies, the China track also includes a panel that will discuss the theme “The China Healthcare Market Operating Environment.”
The following is the preliminary list of companies presenting in the China track:
? Golden Meditech Holdings, Ltd. (HKEX: 801)
? Simcere Pharmaceutical Group (NYSE: SCR)
? Hutchison MediPharma Ltd. (AIM: HCM)
? Concord Medical Services Holdings Ltd. (NYSE: CCM)
? Sinopharm Holding Co. Ltd. (HKEX: 1099)
? Bicon Pharmaceutical Holdings Ltd. (privately held)
? China Resources Medications Group Ltd. (privately held)
? 3SBio Inc. (NSDQ: SSRX)
? ShangPharma Corp. (NYSE: SHP)
? Eddingpharm Inc. (privately held)
? China Kanghui Holdings (NYSE: KH)
? Shanghai Fosun Pharmaceutical (Group) (SHEX: 600196)
? Chindex International, Inc. (NYSE: CHDX)
? Novast Holdings, Ltd. (privately held).
Representatives of ChinaBio? will be attending the Conference and are available to discuss China’s life science sector. (Please email jpm2011@chinabiollc.com.) Greg Scott, ChinaBio’s CEO and founder, will also be speaking on Thursday, January 13, at the New Paradigms conference on funding opportunities in China and elsewhere in Asia (http://www.theconferenceforum.org/NewParadigms-Overview.html).
Disclosure: none.